FDA. Guidance For Industry. Investigator Responsibilities – Protecting The Rights, Safety, And Welfare Of Study Subjects.

I. INTRODUCTION

This guidance represents the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

This guidance provides an overview of the responsibilities of a person who conducts a clinical investigation of a drug, biological product, or medical device (an investigator as defined in 21 CFR 312.3(b) and 21 CFR 812.3(i)). The goal of this guidance is to help investigators better meet their responsibilities with respect to protecting human subjects and ensuring the integrity of the data from clinical investigations. This guidance is intended to clarify for investigators and sponsors FDA’s expectations concerning the investigator’s responsibility (1) to supervise a clinical study in which some study tasks are delegated to employees or colleagues of the investigator or other third parties and (2) to protect the rights, safety, and welfare of study subjects.

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

Source.

Authors:

Center for Drug Evaluation and Research
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research

OCTOBER 2009

 

Clinical Research News

GLP-1 e fertilità: perché i farmaci per la perdita di peso sono discussi nella medicina riproduttiva
Lp(a) alto: un nuovo studio testerà una combinazione di farmaci contro il rischio cardiaco ereditario
Farmaci per la perdita di peso associati a un minor rischio di alcuni tipi di cancro: cosa mostrano i nuovi dati
Dopo ictus ed emorragia cerebrale: un nuovo studio verifica quando sono necessari gli anticoagulanti
Il primo vaccino progettato dall'IA completa la sperimentazione umana
Sangue nelle urine e sospetto tumore: un nuovo test urinario confrontato con cistoscopia e biopsia
Quando l'ecografia mostra un'anomalia ma i test genetici tacciono: in Cina si valuta il WGS (Sequenziamento dell’intero genoma) fetale

Prossimi studi clinici

Clinical Research Jobs

More jobs

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

Sottoscrivi